https://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancerhttps://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancer#u62527Wed, 09 Sep 2026 08:21:14 +0000Patients prescribed the newly approved pancreatic cancer treatment Rasonque from Revolution Medicines face delays as insurance coverage takes weeks to catch up following the FDA greenlight. The drug, known generically as daraxonrasib, successfully targets proteins previously considered undruggable and offers hope for future approvals across various cancer types. While early trial data indicate the medication also shrinks lung tumors by targeting a broad range of RAS mutations, patients currently encounter administrative barriers before they can access the therapy.Why it mattersRevolution Medic https://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancerhttps://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancer#u58879Sun, 06 Sep 2026 09:45:07 +0000The targeted cancer treatment daraxonrasib, previously approved for metastatic pancreatic cancer, demonstrates potential in shrinking tumors among patients with lung cancer. Early trial data indicate the drug targets a broad range of RAS mutations through a novel mechanism. Revolution Medicines is actively seeking to expand the application of the medication to treat metastatic non-small cell lung cancer following findings published in the New England Journal of Medicine. Researchers Salman Punekar and Ron DePinho highlight the treatment as marking a new era for RAS-mutant forms of the disease, https://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancerhttps://www.live-feeds.com/feed/newly-approved-pancreatic-cancer-drug-shows-promise-in-lung-cancer#u57489Fri, 04 Sep 2026 23:53:09 +0000The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggest the drug may also be effective against metastatic non-small cell lung cancer. A Phase 1/2 clinical trial published in the New England Journal of Medicine indicates the drug can shrink tumors in patients with this specific type of lung cancer. While the drug is already approved for pancreatic use, Revolution Medicines is seeking to extend its application to lung cancer patients.Why it mattersRasonque is part of a class of RAS inhibit